1231 / 1851
DAHANCA19: Secondary endpoints
Eriksen, ICHNO 2015
Pts. at risk Events
zalutumumab 301
56
control
307
53
total
608
109
control 80%
zalutumumab 78%
HR: 1.04 [95% CI: 0.72-1.52]
Pts. at risk Events
zalutumumab 301
99
control
307
84
total
608
183
control 69%
zalutumumab 63%
HR: 1.16 [95% CI: 0.87-1.55]
Disease specific Overall survival